Advertisement
Canada markets open in 7 hours 22 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7330
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • Bitcoin CAD

    88,014.34
    +385.12 (+0.44%)
     

  • CMC Crypto 200

    1,390.27
    -6.27 (-0.45%)
     

  • GOLD FUTURES

    2,350.00
    +7.50 (+0.32%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,769.75
    +202.25 (+1.15%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,995.25
    +366.77 (+0.97%)
     

  • CAD/EUR

    0.6830
    +0.0009 (+0.13%)
     

Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·3 min read

For the quarter ended March 2023, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $3.66 billion, representing no change compared to the same period last year. EPS came in at $0.40, compared to $0.55 in the year-ago quarter.

The reported revenue represents a surprise of +1.60% over the Zacks Consensus Estimate of $3.6 billion. With the consensus EPS estimate being $0.57, the EPS surprise was -29.82%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Teva Pharmaceutical Industries Ltd. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenue- International Markets: $492 million versus $493.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Geographic Revenue- North America: $1.77 billion versus $1.74 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.7% change.

  • Geographic Revenue- North America - COPAXONE: $76 million versus $75.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.6% change.

  • Geographic Revenue- North America - BENDEKA / TREANDA: $63 million versus the four-analyst average estimate of $65.49 million. The reported number represents a year-over-year change of -23.2%.

  • Geographic Revenue- North America - AUSTEDO: $170 million compared to the $210.16 million average estimate based on four analysts. The reported number represents a change of +10.4% year over year.

  • Geographic Revenue- North America - Anda: $424 million versus $365.05 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +24% change.

  • Geographic Revenue- Europe - COPAXONE: $59 million versus the four-analyst average estimate of $55.54 million. The reported number represents a year-over-year change of -18.1%.

  • Geographic Revenue- Europe - Respiratory products: $68 million versus $68.10 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.2% change.

  • Geographic Revenue- International Markets - Generic products: $400 million versus the four-analyst average estimate of $395.20 million.

  • Geographic Revenue- International Markets - COPAXONE: $12 million versus the four-analyst average estimate of $7.79 million. The reported number represents a year-over-year change of +20%.

  • Revenue- API sales to third parties: $132 million versus the three-analyst average estimate of $173.65 million. The reported number represents a year-over-year change of -27.1%.

  • Revenue- COPAXONE - Total: $147 million versus the three-analyst average estimate of $139.34 million.

View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>

Shares of Teva Pharmaceutical Industries Ltd. have returned -3.9% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research